Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Dongta Zhong"'
Autor:
Xinyan Gao, Xiaoyan Lin, Mengxin Lin, Yanqin Lan, Yao Wang, Riping Wu, Junde Li, Chuanyong Huang, Dongta Zhong
Publikováno v:
The Turkish Journal of Gastroenterology, Vol 34, Iss 9, Pp 975-981 (2023)
Externí odkaz:
https://doaj.org/article/b2373da6aff34cd985da15e0ef50f404
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Purpose: The prognosis of head and neck squamous cell carcinoma (HNSCC) is poor. Necroptosis is a novel programmed form of necrotic cell death. The prognostic value of necroptosis-associated lncRNAs expression in HNSCC has not been explored.Methods:
Externí odkaz:
https://doaj.org/article/b2776489d36d4a35bf4f80b9d163d4db
Autor:
Xinyan Gao, Xiaoyan Lin, Mengxin Lin, Yanqin Lan, Yao Wang, Riping Wu, Junde Li, Chuanyong Huang, Dongta Zhong
Publikováno v:
Turkish Journal of Gastroenterology; Sep2023, Vol. 34 Issue 9, following p975-981, 8p
Publikováno v:
Tropical Journal of Pharmaceutical Research. 19:2583-2590
Purpose: To determine the association between phosphatidylethanolamine binding protein 1, which is an Raf kinase inhibitor protein (RKIP), and 5-fluorouracil (5-FU) via analysis of the association between RKIP and clinical responses in individuals tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b384ca2e41316c0100b48f1ae7e8f1
https://doi.org/10.4314/tjpr.v19i12.15
https://doi.org/10.4314/tjpr.v19i12.15
Autor:
Xinli Wang, Mengxin Lin, Qing Liu, Hao Chen, Baoyu Yang, Jinhuo Lai, Dongta Zhong, Tao Jiang, Jianwei Zheng, Peifeng Hou, Bin Du, Xiaoyan Lin, Han Wang
Publikováno v:
Advances in Therapy. 37:2829-2840
Cetuximab plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) is the preferred first-line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC). To counter chemotherapy-induced side effects, use of maintenance therapy is s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7cbb6e83e1beb23943db9ff618de0c8
https://doi.org/10.1007/s12325-020-01360-8
https://doi.org/10.1007/s12325-020-01360-8
Autor:
Qian Xu, Dongta Zhong, Yan-Qin Lan, Xinli Wang, Ri-ping Wu, Xin-yan Gao, Ling-jun Kong, Xiaoyan Lin
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:1007-1015
This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). One hundred and seven patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69213b63d3505f735888c2356be98e2e
https://doi.org/10.1007/s00280-018-3576-x
https://doi.org/10.1007/s00280-018-3576-x
Autor:
Yan-Fang Huang, Xinli Wang, Xiaoyan Lin, Wan-Cai Que, Dongta Zhong, Ri-ping Wu, Yan-Qin Lan, Xiao-Bin Huang, Hong-Qiang Qiu, Bin Du, Xin-yan Gao
Publikováno v:
Anti-cancer drugs. 30(3)
The aim of this retrospective analysis was to evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel, 5-fluorouracil, and leucovorin (TFL) as first-line treatment in patients with advanced gastric cancer (AGC). One hundred and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a87ad4be35a9ae181ff49ff4c586c1
https://pubmed.ncbi.nlm.nih.gov/30520775
https://pubmed.ncbi.nlm.nih.gov/30520775
Autor:
Xinli Wang, Yan-Qin Lan, Ri-ping Wu, Dongta Zhong, Jin-Tian Song, Chuan-Yong Huang, Xiaobing Huang
Publikováno v:
Tumori. 104(1)
Purpose:This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer.Methods:One hundred and thirty-eight patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d997ec7cda510208fe90ebb69e07f8
https://pubmed.ncbi.nlm.nih.gov/28777427
https://pubmed.ncbi.nlm.nih.gov/28777427
Autor:
Qing Liu, Xiaoyan Lin, Tao Jiang, Bin Du, Dongta Zhong, Hao Chen, Jianwei Zhen, Xinli Wang, Baoyu Yang
Publikováno v:
Journal of Clinical Oncology. 37:e15004-e15004
e15004 Background: Cetuximab plus FOLFIRI (leucovorin, fluorouracil and irinotecan) is preferred first line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC) patients. However, the side effects often require dose-reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f6805a71152efc822118e86a763e67c
https://doi.org/10.1200/jco.2019.37.15_suppl.e15004
https://doi.org/10.1200/jco.2019.37.15_suppl.e15004
Publikováno v:
Pathology oncology research : POR. 21(4)
This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with S-1 and oxaliplatin (SOX) as first-line treatment in elderly patients with advanced gastric cancer. One hundred and twenty-nine patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0235e0f49afed5408cda08a926cea4d
https://pubmed.ncbi.nlm.nih.gov/25648439
https://pubmed.ncbi.nlm.nih.gov/25648439